Both pathways demonstrate versatility across breast cancer subtypes, including TNBC and HER-2-positive cancers, by addressing distinct metabolic vulnerabilities—ferroptosis targeting iron metabolism and cuproptosis focusing on mitochondrial activity and copper homeostasis. Here, ERBB2 is linked to breast cancer.